Original paper<Br>Telangiectasia macularis eruptiva perstans as the first clinical presentation of systemic mastocytosis

Magdalena Lange; Marek Niedoszytko; Kazimierz Jaśkiewicz; Elżbieta Jasiel-Walikowska; Bogusław Niedoszytko; Krzysztof Lewandowski; Bartosz Wasąg

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2006
vol. 23

Send email

Copy url:

abstract:

Original paper
Telangiectasia macularis eruptiva perstans as the first clinical presentation of systemic mastocytosis

Magdalena Lange

,

Marek Niedoszytko

,

Kazimierz Jaśkiewicz

,

Elżbieta Jasiel-Walikowska

,

Bogusław Niedoszytko

,

Krzysztof Lewandowski

,

Bartosz Wasąg

Post Dermatol Alergol 2006; XXIII, 4: 179–185

Online publish date: 2006/09/08

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Lange M, Niedoszytko M, Jaśkiewicz K, et al. Original paperTelangiectasia macularis eruptiva perstans as the first clinical presentation of systemic mastocytosis. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2006;23(4):179-185.

APA

Lange, M., Niedoszytko, M., Jaśkiewicz, K., Jasiel-Walikowska, E., Niedoszytko, B.,  & Lewandowski, K. et al. (2006). Original paperTelangiectasia macularis eruptiva perstans as the first clinical presentation of systemic mastocytosis. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 23(4), 179-185.

Chicago

Lange, Magdalena, Marek Niedoszytko, Kazimierz Jaśkiewicz, Elżbieta Jasiel-Walikowska, Bogusław Niedoszytko, Krzysztof Lewandowski,  and Bartosz Wasąg. 2006. "Original paperTelangiectasia macularis eruptiva perstans as the first clinical presentation of systemic mastocytosis". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 23 (4): 179-185.

Harvard

Lange, M., Niedoszytko, M., Jaśkiewicz, K., Jasiel-Walikowska, E., Niedoszytko, B., Lewandowski, K.,  and Wasąg, B. (2006). Original paperTelangiectasia macularis eruptiva perstans as the first clinical presentation of systemic mastocytosis. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 23(4), pp.179-185.

MLA

Lange, Magdalena et al. "Original paperTelangiectasia macularis eruptiva perstans as the first clinical presentation of systemic mastocytosis." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 23, no. 4, 2006, pp. 179-185.

Vancouver

Lange M, Niedoszytko M, Jaśkiewicz K, Jasiel-Walikowska E, Niedoszytko B, Lewandowski K et al. Original paperTelangiectasia macularis eruptiva perstans as the first clinical presentation of systemic mastocytosis. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2006;23(4):179-185.

Mastocytosis is a heterogeneous disease characterized by excess proliferation and accumulation of mast cells MC in one or more organs. Cutaneous mastocytosis (CM) is diagnosed on the basis of typical cutaneous lesions and an increase in infiltration of cutaneous MC after the elimination of systemic involvement. Telangiectasia macularis eruptiva perstans, currently named telangiectatic CM, is a rare subset of CM, considered to be a purely cutaneous form of mastocytosis. We present three cases of telangiectatic CM in which diagnostic procedures revealed systemic mastocytosis (SM) in two cases. In these patients skin lesions occurred as the first clinical presentation of SM; their histopathology examination revealed bone marrow involvement, serum tryptase levels were highly elevated, and bone marrow MC expressing CD2 and CD25 were found by flow cytometric analysis. According to WHO criteria in these two cases Indolent SM (ISM) was diagnosed; the third patient requires further clinical observation. Therapy included oral antihistamines (in all patients), PUVA (in one patient) and oral corticosteroids (in one patient) to reduce MC mediator related symptoms.

keywords:

Original paperTelangiectasia macularis eruptiva perstans as the first clinical presentation of systemic mastocytosis

Magdalena Lange , Marek Niedoszytko , Kazimierz Jaśkiewicz , Elżbieta Jasiel-Walikowska , Bogusław Niedoszytko , Krzysztof Lewandowski , Bartosz Wasąg

cutaneous mastocytosis, systemic mastocytosis, telangiectasia macularis eruptiva perstans, diagnosis, treatment

Original paper
Telangiectasia macularis eruptiva perstans as the first clinical presentation of systemic mastocytosis

Magdalena Lange

,

Marek Niedoszytko

,

Kazimierz Jaśkiewicz

,

Elżbieta Jasiel-Walikowska

,

Bogusław Niedoszytko

,

Krzysztof Lewandowski

,

Bartosz Wasąg